NRX Pharmaceuticals, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
NRX Pharmaceuticals, Inc. (NRXP) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $95.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-14
- NRX Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $95.00K, a 41.79% increase year-over-year.
- NRX Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $151.00K, a 1158.33% increase year-over-year.
- NRX Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $68.00K, a 34.62% decline year-over-year.
- NRX Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $67.00K, a 30.93% decline year-over-year.
- NRX Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $228.00K, a 53.09% decline from fiscal 2024.
- NRX Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $486.00K, a 25.58% increase from fiscal 2023.
- NRX Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $387.00K.
- NRX Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2020 was $5.38M.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $95.00K 10-Q · filed 2026-08-14 | $246.00K derived: sum of 2 quarters · filed 2026-08-14 | ||
| 2026-03-31 | $151.00K 10-Q · filed 2026-08-14 | |||
| 2025-12-31 | $228.00K 10-K · filed 2026-03-23 | |||
| 2025-09-30 | $68.00K 10-Q · filed 2025-11-14 | $135.00K derived: sum of 2 quarters · filed 2026-08-14 | $147.00K derived: sum of 3 quarters · filed 2026-08-14 | |
| 2025-06-30 | $67.00K 10-Q · filed 2026-08-14 | $79.00K derived: sum of 2 quarters · filed 2026-08-14 | ||
| 2025-03-31 | $12.00K 10-Q · filed 2026-08-14 | |||
| 2024-12-31 | $486.00K 10-K · filed 2026-03-23 | |||
| 2024-09-30 | $104.00K 10-Q · filed 2025-11-14 | $201.00K derived: sum of 2 quarters · filed 2025-11-14 | $443.00K derived: sum of 3 quarters · filed 2025-11-14 | |
| 2024-06-30 | $97.00K 10-Q · filed 2025-11-14 | $339.00K derived: sum of 2 quarters · filed 2025-11-14 | ||
| 2024-03-31 | $242.00K 10-Q · filed 2025-11-14 | |||
| 2023-12-31 | $387.00K 10-K · filed 2025-03-14 | |||
| 2023-09-30 | $351.00K 10-Q · filed 2024-11-14 | $895.00K derived: sum of 2 quarters · filed 2024-11-14 | $1.59M derived: sum of 3 quarters · filed 2024-11-14 | |
| 2023-06-30 | $544.00K 10-Q · filed 2024-11-14 | $1.24M derived: sum of 2 quarters · filed 2024-11-14 | ||
| 2023-03-31 | $695.00K 10-Q · filed 2024-11-14 | |||
| 2020-12-31 | $5.38M 10-K · filed 2022-03-31 | |||
| 2020-09-30 | $2.69M 10-Q/A · filed 2022-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |